Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

India’s Drug-Price Agency Rankles Drug Makers

This article was originally published in PharmAsia News

Executive Summary

India's drug-pricing regulator is flexing its muscles in going after drug makers for allegedly charging more for their products than rules allow. The National Pharmaceutical Pricing Authority has been going after drug makers even as the two entities are involved in court litigation over the price limits. The fight between the two entities over price caps has led to a stack of court cases, partly because of a concern of a conflict between regulations and policy. But the chief problem may be a lack of coordination between the NPPA and the country's regulator of quality, the Drug Controller General of India. (Click here for more
Advertisement
Advertisement
Advertisement
UsernamePublicRestriction

Register

SC066863

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel